An Open, Single-Center,Single Arm Trial to Evaluate the Efficacy and Safety of Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Phase of Trial: Phase IV
Latest Information Update: 27 May 2015
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Zhejiang Beta Pharma
- 26 Jun 2014 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
- 08 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 20 Nov 2012 New trial record